High IDO or TDO levels are reported as poor prognostic factors in various malignant tumors, such as brain tumor cells [21], ovarian cancer [22], acute myeloid leukemia [23], breast cancer [24], and Hodgkin’s lymphoma [25]. This evidence concerns the gene TDO2 and Hodgkins lymphoma.